Knight Therapeutics is a pan-American (ex-US) specialty pharmaceutical company focused on acquiring, in licensing, out-licensing, marketing, and commercializing innovative prescription pharmaceuticals in Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight Therapeutics shares trade on TSX under the symbol GUD. Headquartered in Montreal, Knight has nearly 700 employees globally.